Estrada, V <br/><br/>
Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.  [electronic resource] 

 -  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America  Jul 2002 
 - 69-76 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-6591 
<br/><br/><label>Standard No.: </label>10.1086/340863  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alkynes<br/>Anti-HIV Agents--therapeutic use<br/>Antiretroviral Therapy, Highly Active<br/>Benzoxazines<br/>Cyclopropanes<br/>Female<br/>HIV Infections--complications<br/>Humans<br/>Male<br/>Metabolic Syndrome<br/>Middle Aged<br/>Oxazines--therapeutic use<br/>Phenotype<br/>Protease Inhibitors--therapeutic use